对扫描的质子束进行独立剂量计算系统的调试和临床实施
Ralf Dreindl1, Marta Bolsa-Ferruz1, Rosa Fayos-Sola1,2
1MedAustron Ion Therapy Center, Wiener Neustadt, Austria.
Journal of applied clinical medical physics
|March 30, 2024
概括
独立剂量计算 (IDC) 软件在质子疗法中成功取代了耗时的患者特定QA,减少了高达90%的QA. 这一进步提高了辐射瘤学的效率和安全性.
科学领域:
- 医学物理 医学物理
- 辐射瘤学 辐射瘤学
- 医疗成像医学成像
背景情况:
- 放射治疗中的实验性患者特异性质量保证 (PSQA) 是资源密集型的,并且错误检测灵敏度低.
- 设施正在过渡到独立剂量计算 (IDC) 结合光束输送QA以取代PSQA.
- 这项研究重点关注myQA iON IDC软件用于质子治疗的调试和临床集成.
研究的目的:
- 报道了用于质子治疗的myQA ion IDC软件工具的投入使用.
- 详细介绍IDC在MedAustron离子治疗中心的临床实施情况.
- 为了验证IDC在替代实验性患者特异性QA方面的有效性.
主要方法:
- 调试涉及验证光束模型,实施和验证临床CT协议,并评估患者治疗数据.
- 分析包括剂量差异图,马指数分布和全球合格率 (GPR).
- 定义和评估了临床工作流程,模拟设置和GPR公差.
主要成果:
- 束模型验证显示与物理测量有很高的一致性 (例如,在±0.2mm内的范围一致性).
- 模拟的3D剂量分布与测量的平均差异为1.8%;CT校准显示系统差异为2.0%.
- 总体通过率为99.4%±0.6% (2%/2毫米) 的头部,头部和部和儿科协议,以及98.9% (3%/3毫米) 的腹部协议.
结论:
- myQA iON IDC软件于2021年成功投入使用并集成到MedAustron临床质子疗法工作流中.
- 自2021年2月以来,IDC已逐步和安全地取代实验性PSQA.
- 实验PSQA的显著降低,在一年后达到了90%.
更多相关视频
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
7.2K
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
2.8K
相关概念视频
Dose Size and Dosing Frequency: Determination Methods
819
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
819
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
401
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
401
